Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

July 11 Quick Takes: Qiming announces $3.2B in new venture funds

Plus Innoviva buying La Jolla in diversification push and updates from Novo Nordisk, Genentech, Sanofi, Alnylam and more

July 12, 2022 1:41 AM UTC

Qiming Venture Partners unveiled a pair of new funds totaling $3.2 billion, with its USD Fund VIII closing at $2.5 billion and its RMB Fund VII having a first close of RMB4.7 billion ($700 million). Both funds exceed their predecessor funds. In January 2021, the firm launched its sixth RMB fund at RMB2.9 billion ($441.1 million) to invest in healthcare and technology companies, bringing the firm’s total assets under management at that point to $5.9 billion. The firm closed its latest U.S. dollar fund, Qiming Venture Partners Fund VII, at $1.2 billion in November 2020. The fresh funding increases the firm's capital raised to $9.4 billion across 18 funds.

As part of its aim to diversify beyond a royalty portfolio, Innoviva Inc. (NASDAQ:INVA) is acquiring 33-year-old La Jolla Pharmaceutical Co. (NASDAQ:LJPC), giving it approved therapies Giapreza angiotensin II for septic shock and Xerava eravacycline for complicated intra-abdominal infections. Both gained approval since late 2017. Innoviva will pay $6.23 per share, including $0.28 per share for incremental cash received in connection with divestiture of a non-core asset; the deal implies an enterprise value of $149 million for La Jolla. Also on Monday, Innoviva completed its acquisition of Entasis Therapeutics Holdings Inc., adding more antibacterials...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article